Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of the Efficacy and Safety of Hypofractionated Stereotactic Radiotherapy and 5FU or Capecitabine With and Without Zometa in Patients With Locally Advanced Pancreatic Adenocarcinoma

NCT03073785 is registered in ClinicalTrials.gov with University of Nebraska as lead sponsor.

NCT NCT03073785
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03073785 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of the Efficacy and Safety of Hypofractionated Stereotactic Radiotherapy and 5FU or Capecitabine With and Without Zometa in Patients With Locally Advanced Pancreatic Adenocarcinoma
Lead sponsor
University of Nebraska
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 16, 2016
Completion date
December 31, 2027
Enrollment
46 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma, recurrent pancreatic carcinoma, stage i pancreatic cancer ajcc v6 and v7, stage ia pancreatic cancer ajcc v6 and v7, stage ib pancreatic cancer ajcc v6 and v7, stage ii pancreatic cancer ajcc v6 and v7, stage iia pancreatic cancer ajcc v6 and v7, stage iib pancreatic cancer ajcc v6 and v7, stage iii pancreatic cancer ajcc v6 and v7, stage iv pancreatic cancer ajcc v6 and v7